In a nutshell This study investigated the outcomes of patients with indolent (painless) refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL) after G-B (obinutuzumab, bendamustine) treatment. This study concluded that G-B improved survival outcomes for NHL patients with similar side effects as bendamustine (Treanda)...
Read MoreIn a nutshell This study compared the quality of life between indolent non-Hodgkin lymphoma patients who are treated with obinutuzumab plus bendamustine or bendamustine alone. The study concluded that patients treated with obinutuzumab plus bendamustine experience prolonged quality of life compared to patients treated with bendamustine...
Read More
In a nutshell This study compared the effectiveness of obinutuzumab (Gazyva) plus CHOP chemotherapy vs obinutuzumab plus bendamustine (Treanda) in treating patients with follicular lymphoma. The study concluded that both obinutuzumab plus CHOP and obinutuzumab plus bendamustine are effective at treating patients with follicular...
Read More
